Two experiments were conducted to study the role of estradiol and progesterone in regulating steroid binding sites in sheep uterine myometrium. Exogenous estradiol increased the concentration of estradiol binding sites in nuclei and subsequently increased the total cell content of estradiol binding sites. Estradiol increased the number of progestogen binding sites (promegestone binding) and may have enhanced the translocation of progestogen binding sites to nuclei. Progesterone decreased the number of progestogen binding sites and blocked the estradiol-induced increase in cytoplasmic estradiol binding sites. Progesterone did not block the estradiol-induced increase in estradiol binding sites in nuclei. Estradiol increased myometrial RNA to DNA ratios within 24 hr of a single injection, whereas progesterone did not. Progesterone blocked the estradiol-induced increase in RNA:DNA. Estradiol apparently promotes the synthesis of both types of binding site. Progesterone, on the other hand, appears to inhibit estrogeninduced synthesis of steroid binding sites by blocking estradiol action at the nucleus. Progesterone may also decrease the number of progestogen binding sites through a mechanism other than its "anti-estrogenic" action.
Introduction
Estrogens and progestins regulate uterine contractility in ewes during the estrous cycle. Uterine contractions characteristic of the cycle can be induced in ovariectomized ewes by injections of these steriods (Croker and Shehon, 1973; Hawk, 1975) . Binding of estrogens and progesterone by cytoplasm and nuclei of ovine myometrium may explain steroid regulation of uterine motility during the estrous cycle (Rexroad, 1981) .
Models for the action of steroids have been based largely on data on rats (for review, see Gorski and Gannon, 1976) . Certain elements of that model have been tested in large animals, especially ewes (for review, see Stormshak, 1979) . Several elements are common to most models. Steroids bind to specific cytoplasmic proteins with high affinity and specificity. A result of that binding is translocation of the ligand-protein complex to the nucleus, resulting in regulation of genome expression. One important aspect of the genome that is regulated is synthesis of steroid binding proteins. Generally, extradiol has been shown to cause replenishment of its own binding site and to cause progesterone binding protein synthesis. Progesterone inhibits estrogen binding protein synthesis and decreases the concentration of progesterone binding sites.
The present study was designed to examine regulation of steroid binding by steroids in ovine myometrium.
Materials and Methods
Binding of estradiol and a synthetic progestin, promegestone (R5020) 4, was studied in cytoplasmic and nuclear fractions of myometrium from parous Rambouillet ewes that had been ovariectomized at least 3 weeks before receiving steroid treatments. 
Exp. I. Binding of estradiol and R5020
to myometrium was determined in ovariectomized ewes necropsied at 4 or 24 hr after injection of estradiol or progesterone. This provided a measure of the effects of the two steroids and of time after injection on the distribution of steroid binding between the cytoplasmic and nuclear fractions of the myometrium. Thirty ewes were assigned at random within replicate to five treatment groups: (1) no treatment; (2) E+4, ewes killed 4 hr after 45 /ag estradiol; (3) E+24, ewes killed 24 hr after 45 /ag estradiol; (4) P+4, ewes killed 4 hr after 10 mg progesterone, and (5) P+24, ewes killed 24 hr after ,10 mg progesterone. Steroids were given as a single IM injection in 1 ml ethanol. Data for only 29 ewes from the six replicates are presented because one ewe was incompletely ovariectomized.
Exp. 2. The object was to determine the effect of different sequences of steroid treatments on the amount and distribution of estradiol binding, R5020 binding and estradiol and progesterone. Thirty-six ewes were assigned at random within replicate to six treatment groups (table 1) . Ewes were killed 12 to 18 hr after the last injection.
Binding and Steroid Assays. All assays for the binding of estradiol and R5020, as well as the radioimmunoassays for measuring progesterone and estradiol, are described in an accompanying paper (Rexroad, 1981) . All binding assays were conducted as saturation analyses at 0 C.
Statistical Procedures.
All data were analyzed as one-way designs by The General Linear Models Procedure of the Statistical Analysis System (Barr et al., 1976) . When significant differences were present, means were compared by Duncan's new multiple range test.
Results

Exp. I.
Estradiol treatment increased the number of unfilled estradiol binding sites in the cytoplasm and in nuclei at 24 hr (figure 1). Progesterone treatment did not significantly alter the number of unfilled estradiol binding sites. Estradiol treatment increased nuclear but not cytoplasmic estradiol concentrations at 4 and 24 hr (figure 2). Progesterone treatment decreased estradiol in the cytoplasm by 24 hours. Estradiol treatment increased the concentration of cytoplasmic R5020 binding sites at 4 and 24 hr and nuclear R5020 binding sites by 24 hr (figure 3). Progesterone treatment did not significantly alter the number of R5020 binding sites at 4 or 24 hours. Estradiol treatment decreased the concentration of progesterone in the cytoplasm and nuclei at 4 hr but not at 24 hr (figure 4). Progesterone treatment decreased the concentration of progesterone in the cytoplasmic and nuclear fractions at both 4 and 24 hours. Estradiol increased the RNA:DNA rates at 24 hr but not at 4 hr (table 2). Progesterone did not alter the ratio.
The dissociation constant for estradiol binding in the cytoplasm averaged .90 -+ .23 • 10-10M (n=35)and did not differsignificandy among treatments. The dissociation constant for estradiol binding in nuclei averaged .93 -+ .12 x IO-I~ (n=35)and did 
E E P P P P P P P P (10) E2P8E1 E E P P P P P P P P E (11) E2P8/EI E E P P P P P P P P/E aNumbers refer to number of days of treatment. bE = 20 ~g estradiol in ethanol twice daily.
Cp = 10 mg progesterone in ethanol twice daily. not vary significantly among treatments. No direct statistical comparison was made between nuclear and cytoplasmic dissociation constants, but they appeared to be similar. The dissociation constants for R5020 binding in cytoplasm and nuclei averaged 3.15 + 1.13 x IO'I~ (n=35) and 17.4 + 7.7 x 10-1~ (n=35), respectively; for cytoplasmic binding, the affinity in controls (4.87 -+ 1.11) was less than the average for all treated groups (2.15 + .40, P<.05), whereas dissociation constants for nuclear progestogen binding did not vary significantly among treatments. Exp. 2. Estradiol treatment, 20 /ag twice daily for 2 days, increased the number of unfilled cytoplasmic and nuclear estrogen binding sites when administered alone (control versus E2, figure 5) or when given after 8 days of progesterone administration (E2P8E1 versus P8 or E2P8).
Progesterone treatment for 8 days decreased cytoplasmic unfilled estrogen binding sites (control versus P8). When estradiol and progesterone were given concurrently on the last day of an 8-day progesterone treatment, progesterone reduced the number of unfilled cytoplasmic and nuclear binding sites (compare E2P8/E1 versus E2P8).
Estradiol increased cytoplasmic estradiol and nuclear estradiol when given on the last day of any sequence of treatments (control versus E2 or E2P8E1 or E2PS/E1, figure 6).
Progesterone treatment did not significantly alter cytoplasmic or nuclear concentrations of estradiol.
Estradiol increased cytoplasmic and nuclear R5020 binding sites when administered alone on the last day of treatment (figure 7, control versus E2, and E2P8 versus E2P8E1). Estradiol did not increase R5020 binding in the cytoplasm when given concurrently with progesterone (compare E2P8 versus E2P8/E1).
Progesterone in the cytoplasm was highly variable, and no treatment significantly altered cytoplasmic progesterone (figure 8). Much of the variation was between replicates. The replicate effect was significant, but the reason for the effect is unknown. Progesterone in the nucleus increased when estradiol was given on the last day of progesterone treatment (compare E2P8 versus E2P8/E1).
Cytoplasmic and nuclear dissociation constants for estradiol binding, averaged over all groups, were 1.28 + .44 x 10"I~ and .82 + .18 • 10"10M, respectively. Two days of estradiol treatment reduced the affinity (larger dissociation constant) of cytoplasmic estradiol binding (2.11 + .39 x 10-10M, group E2; P<.05), and both 2 days of estradiol and estradiol on the day after progesterone treatments reduced the affinity of nuclear estradiol binding (1.04 -+ .04, groups E2 and E2P8E1; P<.05). Cytoplasmic and nuclear dissociation constants, for R5020 binding averaged 2.63 • .24 x 10"1~ and 15.6 • 6.9 x 10-1~ Variation among groups in the affinity of nuclear progestogen binding was significant, with all of the groups that received progesterone having lower K D values than the control group or the group treated with estradiol only (13.0 • 3.3 vs 28.8 • 6.0, P<.05; groups P8, E2P8, E2P8E1 and E2P81E1 vs control and E2).
Estradiol increased the RNA:DNA ratio when given alone for 2 days (table 2; compare control versus E2) or when given after progesterone (compare E2P8 versus E2P8E1). However, when estradiol was given on the last day of progesterone treatment, progesterone blocked the estradiol-induced increase in the RNA:DNA ratio (compare E2P8 versus E2P8/ E1 or E2P8E1 versus E2P8/E1). Progesterone b'c'd'eMeans (2 SEM) in a column within an experiment with no common superscripts differ (P<.05).
alone did not significantly alter the RNA:DNA ratio.
Discussion
The results of the present experiments support the concept that steroids play important roles in regulating concentrations of their own binding sites in myometrium (for reviews, see Gorski and Gannon, 1976; Stormshak, 1979) . Estradiol increased estrogen binding, while progesterone blocked estradiol-induced increases in estrogen binding. A high proportion of cytoplasmic binding sites for estradiol were unfilled. In both experiments, the number of unfilled sites in ovariectomized ewes was increased within 24 hr after an injection of estradiol. Estradiol-induced replenishment of estradiol binding sites has been reported for ovine endometrium (Koligian and Stormshak, 1977a) and for whole uterus (Stone et al., 1978) . Estradiol injections also increased unfilled binding sites in nuclei at 24 hr in Exp. 1. Unfilled nuclear sites could result from contamination with cytoplasm, but Sheridan et al. (1979) have proposed that unfilled binding sites are distribued between the cytoplasm and nucleus, with equilibrium concentrations dependent on the free water content of the two compartments. Jungblut et al. (1978) has reported the presence of activated, steroid-free estrogen receptors in nuclei from pig endometrium, and unfilled binding sites have been reported in nuclei of rabbit corpora lutea (Yuh and Keyes, 1979) . Thus, increased nuclear unfilled binding sites, then, could result from estrogen -induced replenishment of the "cytoplasmic" receptor.
Replenishment of unfilled estradiol binding sites after estradiol treatment could be blocked by progesterone and appears to depend on RNA synthesis. In Exp. 1, estradiol, presumably bound to estradiol binding sites (Rexroad, 1981) , was increased sevenfold at 4 hr after estradiol injection. Increased nuclear estradiol was followed at 24 hr by an increase in the RNA:DNA ratio and in unfilled estradiol binding sites. In Exp. 2, estradiol increased RNA:DNA and the number of unfilled cytoplasmic estradiol binding sites at 24 hr after the first injection, except when progesterone was co-administered with estradiol, in which case neither RNA:DNA nor the number of unfilled cytoplasmic estradiol binding sites was increased. This progesterone block of estradiol-induced synthesis of estradiol binding sites occurred in spite of increased nuclear estradiol. Koligian and Stormshak (1977a,b) have reported that translocation of filled estradiol binding sites from cytoplasm to nuclei occurs in ovine endometrium and that progesterone will block the replenishment of cytoplasmic binding sites that occur after translocation. In ovine myometrium, then, progesterone may exert an anti-estrogenic effect both by blocking estrogen receptor replenishment and by blocking estradiolinduced RNA synthesis. Stone et al. (1979) reported that progesterone was not antiestrogenic in ovine endometrium because it did not block certain estradiol effects, namely estradiol-induced increases in the RNA:DNA ratio. The difference between the present experiment and that of Stone et al. (1979) is that they pretreated ovariectomized ewes with estradiol, resulting in initially high and perhaps nearly maximum RNA:DNA. McCracken (1980) has reported that progesterone is anti-estrogenic in that it blocks estradiolinduced increases in uterine prostaglandin F: ~ release, presumably by blocking estradiolinduced synthesis of oxytocin receptors.
Progestogen binding was regulated like estrogen binding in that it was increased by estradiol. Progestogen binding decreases, however, were probably not due simply to progesterone blockage of estradiol-induced increases in binding. Estradiol treatment increased progestogen binding sites at 24 or 48 hr after treatment in both cytoplasm and nuclei in Exp. 2 and at 24 hr after treatment in cytoplasm and nuclei in Exp. 1. This confirms, for myometrium, that estradiol increases progestogen binding in cytoplasm and whole uterus (Stone et al., 1978) . Progesterone not only decreased estrogen binding receptor replenishment but also reduced concentrations of progestogen binding sites in cytoplasm and nuclei. This finding is in agreement with observations reported for guinea pigs, rabbits and other species (Vu Hai et al., 1977; Batra, 1979; Jonne et al., 1978) . The reduction in progestogen binding sites after 8 days of progesterone treatment in Exp. 2 could have resulted from progesterone-induced catabolism of the binding site. Alternatively, progesterone blockage of estradiol binding site synthesis could result in decreased progestogen binding site synthesis if basal concentrations are dependent on estrogens.
Estradiol may be important in regulating the tissue turnover of progesterone. In Exp. 1, in which ewes were given only one steroid, estradiol initially decreased both cytoplasmic and nuclear progesterone while increasing the number of cytoplasmic binding sites at 4 and 24 hr and the number of nuclear binding sites at 24 hours. However, in Exp. 2, coadministration of estradiol and progesterone resulted in increased progesterone in the nucleus at 24 hours. Estradiol may cause translocation of filled progesterone sites from cytoplasm to nucleus and subsequent catabolism of both the binding site of progesterone, resulting in the decreases observed initially in Exp. 1. Increases in nuclear progesterone in Exp. 2 might have resulted from continued translocation of filled sites because of the presence of exogenous progesterone in the plasma.
The results of the present experiments on steroid regulation of steroid binding, along with those in the literature, provide a partial explanation for the variations in estrogen and progesterone binding and tissue concentrations of estradiol and progesterone observed during the estrous cycle (Rexroad, 1981) . Estradiol binding and estradiol were greatest at estrus in both nuclei and cytoplasm, as would be expected from estradiol induction of the synthesis of its own binding agent and its translocation of binding sites to the nucleus. The decrease in estradiol binding throughout the estrous cycle probably resulted from two factors: (1) a decrease in ovarian estradiol secretion after estrus and (2) increased progesterone secretion. Progestogen binding was highest at estrus and on day 3 and greatest in nucleus on days 6 to 9. High concentrations of progestogen binding in the cytoplasm on days 0 to 3 and high concentrations in nuclei on days 6 to 9 would have resulted from (1)estradiol-induced synthesis of progestogen binding and (2) estradiol-facilitated movement of the binding site to the nucleus. The observed decreases in cytoplasmic progestin binding during the cycle probably resulted from (1) progesteroneinduced deactivation (turnover) and(or) (2) the lack of appreciable estrogenic stimulation of the synthesis of new binding sites. The high levels of progesterone in the nucleus on days 6 to 9 probably resulted from increasing plasma progesterone, coupled with residual estradiol effects, resulting in translocation of progesterone to the nucleus.
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